The FDA placed a partial clinical hold on PepGen’s Phase 2 study for a rare muscle disorder after reviewing preclinical data and raising product‑characterization questions. The stoppage affects the company’s sole clinical asset and forces an immediate reassessment of timelines and regulatory interactions. Analysts and market commentary linked the hold to broader FDA resourcing and review‑process challenges, noting interruptions across several small biotech programs. PepGen now faces additional data requests and possible delays to pivotal plans while the agency and company address the regulator’s concerns.